Pilot study to investigate the clinical effect of orally inhaled AP301 on treatment of primary graft dysfunction (PGD) in mechanically ventilated patients after primary lung transplantation

Trial Profile

Pilot study to investigate the clinical effect of orally inhaled AP301 on treatment of primary graft dysfunction (PGD) in mechanically ventilated patients after primary lung transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2017

At a glance

  • Drugs Solnatide (Primary)
  • Indications Reperfusion injury
  • Focus Proof of concept; Therapeutic Use
  • Sponsors APEPTICO Forschung und Entwicklung
  • Most Recent Events

    • 30 Sep 2017 Primary endpoint (MeanPaO2/FIO2 ratio) has been met, according to results published in the Journal of Heart and Lung Transplantation.
    • 30 Sep 2017 Results assessing the efficacy and tolerability of orally inhaled AP 301 for the treatment of primary graft dysfunction in mechanically ventilated patients following primary lung transplantation, were published in the Journal of Heart and Lung Transplantation.
    • 23 Jul 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top